ClinicalTrials.gg
CompletedNCT02180477Updated Jul 8, 2014

Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers

A Phase 1 interventional study of UHAC 62 XX - TF1 tablet and UHAC 62 XX - TF2 tablet in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Study to investigate the relative bioavailability of UHAC 62 XX capsule and two different tablet formulations (TF1 and TF2), and to obtain data for rational design of a subsequent pivotal bioequivalence (BE) study between capsule and tablet formulations.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 20 and \<= 35 years
  • Weight: >= 18.5 and \< 25 (Weight (kg) / Height (m²)
  • Subjects who are judged by the investigator to be appropriate as the subjects of the study based on results of screening test
  • Subjects who volunteer to participate and are able to fully understand and agree with this study by written

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal ulcer or surgery of gastrointestinal tract (except appendectomy)
  • History of to meloxicam and/or salicylate (aspirin) and/or Non-steroidal anti-inflammatory drugs (NSAIDs)
  • History of aspirin induced asthma (bronchial asthma induced by NSAIDs)
  • History of alcohol or drug abuse
  • Participation to another trial with an drug within 4 months prior to the administration
  • Whole blood donation more than 400 ml within 3 months prior to the administration
  • Whole blood donation more than 100 ml within 1 month prior to the administration
  • Donation of constituent of blood of more than 400 ml within 1 month prior to the administration
  • Any medication within 10 days prior to the administration
  • Excessive physical activities within 7 days prior to the administration
  • Alcohol drinking within 3 days prior to the administration
  • History of orthostatic hypotension, fainting spells or blackouts
  • Other than above, those who are judged by the investigator to be inappropriate as the subjects of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    UHAC 62 XX TF1 tablet

    Drug: UHAC 62 XX - TF1 tablet · Drug: UHAC 62 XX - TF2 tablet · Drug: UHAC 62 XX - capsules

  • Experimental
    UHAC 62 XX TF2 tablet

    Drug: UHAC 62 XX - TF1 tablet · Drug: UHAC 62 XX - TF2 tablet · Drug: UHAC 62 XX - capsules

  • Active comparator
    UHAC 62 XX capsule

    Drug: UHAC 62 XX - TF1 tablet · Drug: UHAC 62 XX - TF2 tablet · Drug: UHAC 62 XX - capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum observed concentration in plasma)

    Time frame: up to 72 hours after administration

  2. AUC 0-72hr (Area under the concentration-time curve in plasma from zero time to 72 hours)

    Time frame: up to 72 hours after administration

Secondary outcomes

  1. tmax (Time to reach maximum concentration)

    Time frame: up to 72 hours after administration

  2. t1/2 (Terminal half-life in plasma)

    Time frame: up to 72 hours after administration

  3. AUC 0-infinity (Area under the concentration-time curve in plasma from zero time to infinity)

    Time frame: up to 72 hours after administration

  4. MRT 0-t (Mean residence time in the body from zero time to the time of the last quantifiable drug concentration)

    Time frame: up to 72 hours after administration

  5. Number of patients with adverse events

    Time frame: up to 14 days after last administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001 and a primary completion of Dec 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2014
First posted
Jul 2, 2014
Start
Nov 2001
Primary completionActual
Dec 2001
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02180477
Responsible party
Sponsor
First posted
Jul 2, 2014
Start date
Nov 2001
Primary completion
Dec 2001
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion